3Cherubini M, Baxa P, Guarino G. The oestrogen-progesterone receptor ratio: an indicator of breast cancer evolution[ J ]. Chir Ital, 2002, 54(4) : 423-428.
4Riou G, Mathieu MC, Barrois M, et al. C-erbB-2(HER-2/neu) gene amplification is a better indicator of poor prognosis than protein over-expression in operable breast-cancer patients [ J ]. Int J Cancer, 2001, 95(4) : 266-270.
5Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendation for human epidermal growth factor 2 testing in breast cancer[J]. Arch Pathol Lab Med, 2007, 131 ( 1 ) : 18-43.
6Mylonas I, Makovitzky J, Jeschke U, et al. Expression of HER2/neu, steroid receptors( ER and PR) , Ki67 and P53 in invasive mammary ductal carcinoma associated with ductal carcinoma in situ (DCIS) versus invasive breast cancer alone [J]. Anticancer Res, 2005, 25(3A) : 1719-1723.
7Beenken SW, Grizzle WE, Crowe DR, et al. Molecular biomarkers for breast cancer prognosis : coexpression of C-erbB-2 and P53[J]. Ann Surg, 2001,233(5) : 630-638.
8Perou CM, Sφrlie T, Eisen MB, et al. Molecular portraits of human breast tumors[J]. Nature, 2000, 406(6797) : 747-752.
9Payton-Stewart F,Tilghman SL,Williams LG.Benzimidazoles diminish ERE transcriptional activity and cell growth in breast cancer cells[J].Biochem Biophys Res Commun,2014,450(4):1358-1362.
10Locker GY.Hormonal therapy of breast cancer[J].Cancer Treat Rev,1998,24(3):221-240.
